Programmed death (PD)-1:PD-ligand 1/PD-ligand 2 pathway inhibits T cell effector functions during human tuberculosis

Journal of Immunology

Volumn 181, Issue 1, 2008, Pages 116-125

  Jurado, Javier O ^a   Alvarez, Ivana B ^a   Pasquinelli, Virginia ^a   Martínez, Gustavo J ^a   Quiroga, María F ^a   Abbate, Eduardo ^b   Musella, Rosa M ^b   Chuluyan, H Eduardo ^a   García, Verónica E ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b HOSPITAL F J MUÑIZ   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INHIBITOR PROTEIN; LIGAND; PD 1 LIGAND; PD 2 LIGAND; PROGRAMMED DEATH 1 PROTEIN; RECEPTOR PROTEIN; UNCLASSIFIED DRUG; ANTIGEN; APOPTOSIS REGULATORY PROTEIN; CD150 ANTIGEN; CD274 PROTEIN, HUMAN; CELL SURFACE RECEPTOR; LEUKOCYTE ANTIGEN; PDCD1 PROTEIN, HUMAN; PDCD1LG2 PROTEIN, HUMAN; SIGNAL PEPTIDE;

ARTICLE; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DEGRANULATION; HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TUBERCULOSIS; BIOSYNTHESIS; CELL CULTURE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MYCOBACTERIUM TUBERCULOSIS; PROTEIN BINDING; T LYMPHOCYTE;

ANTIGENS; ANTIGENS, CD; APOPTOSIS REGULATORY PROTEINS; CELLS, CULTURED; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERFERON TYPE II; LYMPHOCYTE ACTIVATION; MYCOBACTERIUM TUBERCULOSIS; PROTEIN BINDING; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TUBERCULOSIS;

EID: 47949107182     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.181.1.116     Document Type: Article

References (61)

1. Kaufmann, S. H. 2001. How can immunology contribute to the control of tuberculosis? Nat. Rev. Immunol. 1: 20-30.
2. + T cells requires the production of 7 interferon. Infect. Immun. 66: 830-834.
3. Zhang, M, J. Gong, D. V. Iyer, B. E. Jones, R. L. Modlin, and P. F. Barnes. 1994. T cell cytokine responses in persons wilh tuberculosis and human immunodeficiency virus infection. J. Clin. Invest. 94: 2435-2442.
4. Zhang. M., Y. Lin, D. V. Iyer. J. Gong, J. S. Abrams. and P. F. Barnes. 1995 T-cell cytokine responses in human infection with Mycobacterium tuberculosis. Infect. Immun. 63: 3231-3234.
5. tck. Blood 97: 2351-2357.
6. Thompson. C. B., and J. P. Allison. 1997. The emerging role of CTLA-4 as an immune attenuator. Immunity 7: 445-450.
7. Oosterwegel, M. A., R. J. Greenwald, D. A. Mandelbrot, R. B. Lorsbach, and A. H. Sharpe. 1999. CTLA-4 and T cell activation. Curr. Opin. Immunol. 11: 294-300.
8. Pasquinelli, V., M. F. Quiroga, G. J. Martinez, L. C. Zorrilla, R. M. Musella, M. M. Bracco, L. Belmonte, A. Malbran, L. Fainboim, P. A. Sieling, and V. E. Garcia. 2004. Expression of signaling lymphocytic activation molecule-associated protein interrupts IFN-γ production in human tuberculosis. J. Immunol. 172: 1177-1185.
9. Quiroga, M. F., V. Pasquinelli, G. J. Martinez, J. O. Jurado, L. C. Zorrilla, R. M. Musella, E. Abbate, P. A. Sieling, and V. E. Garcia. 2006. Inducible costimulator: a modulator of IFN-γ production in human tuberculosis. J. Immunol. 176: 5965-5974.
10. Quiroga, M. F., J. O. Jurado, G. J. Martinez, V. Pasquinelli, R. M. Musella, E. Abbate, A. C. Issekutz, M. M. Bracco, A. Malbran, P. A. Sieling, et al. 2007. Cross-talk between CD31 and the signaling lymphocytic activation molecule-associated protein during interferon-γ production against Mycobacterium tuberculosis. J. Infect. Dis. 196: 1369-1378.
11. Ishida, Y., Y. Agata, K. Shibahara, and T. Honjo. 1992. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 11: 3887-3895.
12. Agata, Y., A. Kawasaki. H. Nishimura, Y. Ishida, T. Tsubata, H. Yagita, and T. Honjo. 1996. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int. Immunol. 8: 765-77Z
13. Freeman, G. J., A. J. Long, Y. Iwai, K. Bourque, T. Chemova, H. Nishimura, L. J. Fitz, N. Malenkovich, T. Okazaki, M. C. Byme, el al. 2000. Engagement of the PD-I immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192: 1027-1034.
14. Latchman, Y., C. R. Wood, T. Chemova, D. Chaudhary, M. Borde, I. Chemova, Y. Iwai, A. J. Long, J. A. Brown, R. Nunes, et al. 2001. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol. 2: 261-268.
15. Tseng, S. Y., M. Otsuji, K. Gorski, X. Huang, J. E. Slansky, S. I. Pai, A. Shalabi, T. Shin, D. M. Pardoll, and H. Tsuchiya. 2001. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J. Exp. Med. 193: 839-846.
16. Sharpe, A. H., E. J. Wherry, R. Ahmed, and G. J. Freeman. 2007. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat. Immunol. 8: 239-245.
17. Garcia, V. E., P. A. Sieling, J. Gong, P. F. Barnes, K. Uyemura, Y. Tanaka, B. R. Bloom, C. T. Morita, and R. L. Modlin. 1997. Single-cell cytokine analysis of γδ T cell responses to nonpeptide myeobacterial antigens. J. Immunol. 159: 1328-1335.
18. + T cells by a flow cytometric assay for degranulation. J. Immunol. Methods 281: 65-78.
19. + T cells and is overcome by IL-2. Eur. J. Immunol. 32: 634-643.
20. Spellberg, B., and J. E. Edwards, Jr. 2001. Type 1/type 2 immunity in infectious diseases. Clin. Infect. Dis. 32: 76-102.
21. Chan, E. D., J. Chan, and N. W. Schluger. 2001. What is the role of nitric oxide in murine and human host defense against tuberculosis: current knowledge. Am. J. Respir. Cell Mol. Biol. 25: 606-612.
22. Dorman, S. E., and S. M. Holland. 2000. Interferon-y and interleukin-12 pathway defects and human disease. Cytokine Growth Factor Rev. 11: 321-333.
23. Bennett, F., D. Luxenberg, V. Ling, I. M. Wang, K. Marquette, D. Lowe, N. Khan, G. Veldman, K. A. Jacobs, V. E. Valge-Archer, et al. 2003. Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28. IL-7, and IL-I5 responses. J. Immunol. 170: 711-718.
24. Ellner, J. J., P. F. Barnes, R. S. Wallis, and R. L. Modlin. 1988. The immunology of tuberculous pleurisy. Semin. Respir. Infect. 3: 335-342.
25. Loke, P., and J. P. Allison. 2003. PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc. Natl. Acad. Sci. USA 100: 5336-5341.
26. H12 and phosphatidylcholine binding. Eur. J. Immunol. 37: 2405-2410.
27. Chen, L. 2004. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat. Rev. Immunol. 4: 336-347.
28. Butte, M. J., M. E. Keir, T. B. Phamduy, A. H. Sharpe, and G. J. Freeman. 2007. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 27: 111-122.
29. Bukczynski, J., T. Wen, C. Wang, N. Christie, J. P. Routy, M. R. Boulassel, C. M. Kovacs, K. S. Macdonald, M. Ostrowski, R. P. Sekaly, et al. 2005. Enhancement of HIV-spccific CD8 T cell responses by dual costimulation with CD80 and CD137L. J. Immunol. 175: 6378-6389.
30. Lee, S. W., Y. Park, A. Song, H. Cheroutre, B. S. Kwon, and M. Croft. 2006. Functional dichotomy between OX40 and 4-IBB in modulating effector CD8 T cell responses. J. Immunol. 177: 4464-4472.
31. Dawicki. W., E. M. Bertram, A. H. Sharpe, and T. H. Watts. 2004. 4-IBB and OX40 act independently to facilitate robust CDS and CD4 recall responses. J. Immunol. 173: 5944-5951.
32. Hirano, F., K. Kaneko, H. Tamura, H. Dong, S. Wang, M. Ichikawa, C. Rietz, D. B. Flies, J. S. Lau, G. Zhu, et al. 2005. Blockade of B7-HI and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 65: 1089-1096.
33. Loke, P., and J. P. Allison. 2004. Emerging mechanisms of immune regulation: the extended B7 family and regulatory T cells. Arthritis Res. Ther. 6: 208-214.
34. Dong, H., G. Zhu, K. Tamada, and L. Chen. 1999. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat. Med. 5: 1365-1369.
35. Barber, D. L., E. J. Wherry, D. Masopust, B. Zhu, J. P. Allison, A. H. Sharpe, G. J. Freeman, and R. Ahmed. 2006. Restoring function in exhausted CDS T cells during chronic viral infection. Nature 439: 682-687.
36. Day, C. L., D. E. Kaufmann, P. Kiepiela, J. A. Brown, E. S. Moodley, S. Reddy, E. W. Mackey, J. D. Miller, A. J. Leslie, C. DePierres, et al. 2006. PD-1 expression on HIV-spccific T cells is associated with T-cell exhaustion and disease progression. Nature 443: 350-354.
37. + T cells identifies functionally and phe-notypically defined memory T cells during acute resolving hepatitis B virus infection. J. Virol. 80: 3532-3540.
38. Urbani, S., B. Amadei, D. Tola, M. Massari, S. Schivazappa, G. Missale, and C. Ferrari. 2006. PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-spccific CDS exhaustion. J. Virol. 80: 11398-11403.
39. Das, S., G. Suarez, E. J. Beswick, J. C. Sierra, D. Y. Graham, and V. E. Reyes. 2006. Expression of B7-H1 on gastric epithelial cells: its potential role in regulating T cells during Helicobacter pylori infection. J. Immunol. 176: 3000-3009.
40. Cohen, N., J. Morisset, and D. Emilie. 2004. Induction of tolerance by Porphy-romonas gingivalis on APCS: a mechanism implicated in periodontal infection. J. Dent. Res. 83: 429-433.
41. Sable, S. B., R. Kumar, M. Kalra, I. Verma, G. K. Khuller, K. Dobos, and J. T. Belisle. 2005. Peripheral blood and pleural fluid mononuclear cell responses to low-molecular-mass secretory polypeptides of Mycobacterium tuberculosis in human models of immunity to tuberculosis. Infect. Immun. 73: 3547-3558.
42. Nakae, S., H. Suto, M. Iikura, M. Kakurai, J. D. Sedgwick, M. Tsai, and S. J. Galli. 2006. Mast cells enhance T cell activation: importance of mast cell costimulatory molecules and secreted TNF. J. Immunol. 176: 2238-2248.
43. Garcia, V. E., M. F. Quiroga, M. T. Ochoa, L. Ochoa, V. Pasquinelli, L. Fainboim, L. M. Olivares, R. Valdez, D. O. Sordelli, G. Aversa, et al. 2001. Signaling lymphocytic activation molecule expression and regulation in human intracellular infection correlate with Th1 cytokine patterns. J. Immunol. 167: 5719-5724.
44. Okamoto, M., Y. Hasegawa, T. Hara, N. Hashimoto, K. Imaizumi, K. Shimokata, and T. Kawabe. 2005. T-helpcr type 1/T-helper type 2 balance in malignant pleural effusions compared to tuberculous pleural effusions. Chest 128: 4030-4035.
45. Liang, S. C., Y. E. Latchman, J. E. Buhlmann, M. F. Tomczak, B. H. Horwitz, G. J. Freeman, and A. H. Sharpe. 2003. Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur. J. Immunol. 33: 2706-2716.
46. Flies, D. B., and L. Chen. 2007. The new B7s: playing a pivotal role in tumor immunity. J. Immunother. 30: 251-260.
47. Nishimura, H., M. Nose, H. Hiai, N. Minato, and T. Honjo. 1999. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11: 141-151.
48. Latchman, Y. E., S. C. Liang, Y. Wu, T. Chemova, R. A. Sobel, M. Klemm, V. K. Kuchroo, G. J. Freeman, and A. H. Sharpe. 2004. PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc. Natl. Acad. Sci, USA 101: 10691-10696.
49. Keir, M. E., S. C. Liang, I. Guleria, Y. E. Latchman, A. Qipo, L. A. Albacker, M. Koulmanda, G. J. Freeman, M. H. Sayegh, and A. H. Sharpe. 2006. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J. Exp. Med. 203: 883-895.
50. + T cell activation. Eur. J. Immunol. 36: 2472-2482.
51. Blocki, F. A., S. Radhakrishnan, V. P. Van Keulen, K. L. Heckman, B. Ciric, C. L. Howe, M. Rodriguez, E. Kwon, and L. R. Pease. 2006. Induction of a gene expression program in dendritic cells with a cross-linking IgM antibody to the co-stimulatory molecule B7-DC. FASEB J. 20: 2408-2410.
52. + Tcell activation and cytolysis. Eur. J. Immunol. 33: 3117-3126.
53. Dong, H., S. E. Strome, D. R. Salomao, H. Tamura, F. Hirano, D. B. Flies, P. C. Roche, J. Lu, G. Zhu, K. Tamada, et al. 2002. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8: 793-800.
54. Hadrup, S. R., O. Braendstrup, G. K. Jacobsen, S. Mortensen, L. O. Pedersen, T. Seremet, M. H. Andersen, J. C. Becker, and P. T. Straten. 2006. Tumor infiltrating lymphocytes in seminoma lesions comprise clonally expanded cytotoxic T cells. Int. J. Cancer 119: 831-838.
55. Mittendorf, E. A., C. E. Storrer, C. D. Shriver, S. Ponniah, and G. E. Peoples. 2005. Evaluation of the CD107 cytotoxicity assay for the detection of cytolytic CD8+ cells recognizing HER2/neu vaccine peptides. Breast Cancer Res. Treat. 92: 85-93.
56. + T cell survival in HIV infection. J. Exp. Med. 203: 2281-2292.
57. + T cells leads to reversible immune dysfunction. Nat. Med. 12: 1198-1202.
58. Jun, H., S. K. Seo, H. Y. Jeong, H. M. Seo, G. Zhu, L. Chen, and I. H. Choi. 2005. B7-H1 (CD274) inhibits the development of herpetic stromal keratitis (HSK). FEBS Lett. 579: 6259-6264.
59. + T lymphocytes in the liver. J. Immunol. 178: 2714-2720.
60. Wolf, A. J., L. Desvignes, B. Linas, N. Banaiee, T. Tamura, K. Takatsu, and J. D. Emst. 2008. Initiation of the adaptive immune response to Mycobacterium tuberculosis depends on antigen production in the local lymph node, not the lungs. J. Exp. Med. 205: 105-115.
61. Alfaro, C., O. Murillo, I. Tirapu, A. Azpilicueta, E. Huarte, A. Anna, L. Arribillaga, J. L. Perez-Gracia, M. Bendandi, J. Prieto, et al. 2006. [The im-munotherapy potential of agonistic anti-CD 137 (4-IBB) monoclonal antibodies for malignancies and chronic viral diseases]. An. Sist. Sanit. Navar. 29: 77-96.